| __timestamp | BioCryst Pharmaceuticals, Inc. | Eli Lilly and Company |
|---|---|---|
| Wednesday, January 1, 2014 | 51796000 | 4733600000 |
| Thursday, January 1, 2015 | 72758000 | 4796400000 |
| Friday, January 1, 2016 | 61008000 | 5243900000 |
| Sunday, January 1, 2017 | 66962000 | 5281800000 |
| Monday, January 1, 2018 | 84888000 | 5051200000 |
| Tuesday, January 1, 2019 | 107068000 | 5595000000 |
| Wednesday, January 1, 2020 | 122964000 | 6085700000 |
| Friday, January 1, 2021 | 208808000 | 7025900000 |
| Saturday, January 1, 2022 | 253297000 | 7190800000 |
| Sunday, January 1, 2023 | 216566000 | 9313400000 |
| Monday, January 1, 2024 | 14271000000 |
Data in motion
In the ever-evolving world of pharmaceuticals, innovation is key to staying ahead. Eli Lilly and Company and BioCryst Pharmaceuticals, Inc. are two giants in the industry, each with a distinct approach to research and development (R&D) spending. Over the past decade, Eli Lilly has consistently outpaced BioCryst in R&D investment, with an average annual expenditure nearly 50 times greater. In 2023, Eli Lilly's R&D spending reached a staggering $9.3 billion, marking a 97% increase since 2014. In contrast, BioCryst's R&D expenses grew by 318% over the same period, peaking at $253 million in 2022. This disparity highlights Eli Lilly's robust commitment to innovation, while BioCryst's rapid growth underscores its strategic focus on targeted advancements. As the pharmaceutical landscape continues to shift, these companies' R&D priorities will play a crucial role in shaping future breakthroughs.
R&D Insights: How Eli Lilly and Company and Intra-Cellular Therapies, Inc. Allocate Funds
Who Prioritizes Innovation? R&D Spending Compared for Eli Lilly and Company and Genmab A/S
Who Prioritizes Innovation? R&D Spending Compared for Eli Lilly and Company and Rhythm Pharmaceuticals, Inc.
Who Prioritizes Innovation? R&D Spending Compared for Eli Lilly and Company and Celldex Therapeutics, Inc.
Comparing Innovation Spending: Eli Lilly and Company and Evotec SE
Who Prioritizes Innovation? R&D Spending Compared for Genmab A/S and BioCryst Pharmaceuticals, Inc.
Research and Development: Comparing Key Metrics for Pharming Group N.V. and BioCryst Pharmaceuticals, Inc.
Analyzing R&D Budgets: Apellis Pharmaceuticals, Inc. vs BioCryst Pharmaceuticals, Inc.
Research and Development Investment: Ligand Pharmaceuticals Incorporated vs BioCryst Pharmaceuticals, Inc.
R&D Spending Showdown: Supernus Pharmaceuticals, Inc. vs BioCryst Pharmaceuticals, Inc.
Research and Development: Comparing Key Metrics for Amphastar Pharmaceuticals, Inc. and BioCryst Pharmaceuticals, Inc.